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Abstract
Background: A substantial genetic component accounts for Autism Spectrum Disorders (ASD) aetiology, with some
rare and common genetic risk factors recently identified. Large collections of DNAs from thoroughly characterized ASD
families are an essential step to confirm genetic risk factors, identify new variants and investigate genotype-phenotype
correlations. The Italian Autism Network aimed at constituting a clinical database and a biorepository of samples
derived from ASD subjects and first-degree relatives extensively and consistently characterized by child psychiatry
centers in Italy.
Methods: The study was approved by the ethical committee of the University of Verona, the coordinating site, and by
the local ethical committees of each recruiting site. Certified staff was specifically trained at each site for the overall
study conduct, for clinical protocol administration and handling of biological material. A centralized database was
developed to collect clinical assessment and medical records from each recruiting site. Children were eligible for
recruitment based on the following inclusion criteria: age 4–18 years, at least one parent or legal guardian giving
voluntary written consent, meeting DSM-IV criteria for Autistic Disorder or Asperger’s Disorder or Pervasive
Developmental Disorder NOS. Affected individuals were assessed by full psychiatric, neurological and physical
examination, evaluation with ADI-R and ADOS scales, cognitive assessment with Wechsler Intelligence Scale for
Children or Preschool and Primary, Leiter International Performance Scale or Griffiths Mental Developmental Scale.
Additional evaluations included language assessment, the Krug Asperger’s Disorder Index, and instrumental
examination such as EEG and structural MRI. DNA, RNA and plasma were collected from eligible individuals and
relatives. A central laboratory was established to host the biorepository, perform DNA and RNA extraction and
lymphocytes immortalisation.
Discussion: The study has led to an extensive collection of biological samples associated with standardised clinical
assessments from a network of expert clinicians and psychologists. Eighteen sites have received ADI/ADOS training,
thirteen of which have been actively recruiting. The clinical database currently includes information on 812 individuals
from 249 families, and the biorepository has samples for 98% of the subjects. This effort has generated a highly
valuable resource for conducting clinical and genetic research of ASD, amenable to further expansion.
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Background
Autism Spectrum Disorders (ASD), also previously referred
to as Pervasive Developmental Disorders (PDD), are a
group of neurodevelopmental disorder with onset in early
childhood characterized by a triad of core symptoms: im-
paired social interaction, compromised language and com-
munication and repetitive and narrow pattern of behaviors
and interests. Many neuropsychiatric conditions and symp-
toms are often present in addition to core symptoms in
ASD; the most common being mental retardation, hyper-
activity, epilepsy, aggressive behaviours. Autism or Autistic
Disorder (AD), is the most common and well-known form
of ASD that includes Asperger Syndrome (AS), Pervasive
Developmental Disorder Not Otherwise Specified (PDD –
NOS), Childhood Disintegrative Disorder (CDD) and Rett
Syndrome (RS). All above subtypes are falling under the
single diagnostic category of autism spectrum disorders,
according to the new revision of the Diagnostic and Statis-
tical Manual of Mental Disorders (DSM-5) [1]. AS is a less
severe variant of AD, in which there is no cognitive deficit
or language impairment. PDD – NOS defines a subtype of
AD that characterizes subjects who are on the autism
spectrum but do not fully meet the criteria for other AD
or other ASD, and it was considered a separate diagnostic
category in the DSM-IV. CDD and RS are more rare
forms of ASD and show more distinct features from the
rest of ASD [2]. CDD is a rare and not very well-known
variant of ASD characterized by normal development
followed by marked regression in many skills that begin
after the age of two [3, 4]. Rett Syndrome (RS) is caused in
80% of cases by sporadic mutations of MECP2 located on
Xq28. As opposed to AD, RS is more common in females.
It has a lifetime prevalence of about 1 in 20,000 females
and is characterized by apparently normal development
for the first 6–18 months of life, followed by a period of
regression in language and motor skills [5]. Both CDD
and RS represent nosologically distinct disorders from
AD, AS and PDD – NOS. In this manuscript, we use the
term ASD to refer to AD, AS and PDD-NOS since the
three diagnoses can be considered as a continuum rather
than clear distinct disorders, consistently with the newly
revised DSM-5. Within each of the three diagnostic cat-
egories, clinical heterogeneity is substantial. The fact that
AD children share the same diagnostic categories does
not imply they share set or severity of core and
ASD-associated symptoms. Also, heterogeneity on ASD
aetiology is more than likely. Several etiological
hypotheses exist, such as altered synaptic dysfunction [6]
leading to imbalanced excitatory and inhibitory neuro-
transmission [7]. However, a unifying aetiological theory is
still lacking, and it is more than likely that the clinical het-
erogeneity is also paralleled by etiological heterogeneity.
Prevalence of ASD is reported to be much higher in
most recent studies as compared to studies conducted a
decade ago. Recent epidemiological studies indicate a
worldwide prevalence for ASD ranging from 0.6 to 0.7%
with an approximate males to females ratio of 4–5 to 1
[8, 9], as compared to the prevalence of less than 0.2%
in earlier investigations [10]. The interpretation of in-
creased prevalence detected in recent studies is not
straightforward and has raised controversial debates on
the potential causes. The original paper published in
Lancet [11] that initiated the controversy on vaccines as
a putative cause of autism has been recently retracted by
the Journal since fraud has been detected. The vast ma-
jority of the scientific community agrees on the unlikeli-
hood of vaccination as a cause. One confounding factor,
when reporting prevalence estimates, could be the
change over time of diagnostic criteria for ASD, making
the comparisons of epidemiological studies more diffi-
cult. It is commonly believed that the increase in the
overall reported prevalence is mostly due to the develop-
ment of more comprehensive ascertainment and to the
expansion of diagnostic categories, which include milder
forms of the disorder [12].
Considerable evidence from twin studies indicates a
substantial genetic component in the aetiology of ASD.
ASD heritability has been estimated to be between 80
and 90% according to recent family and twin studies
[13]. Monozygotic twin concordance has been found to as
high as > 88%, whilst in dizygotic pairs and siblings the
concordance rates are > 30% and > 15%, respectively,
higher than what previously reported, suggesting a signifi-
cant environmental contribution to ASD [14]. Substantial
heterogeneity also exists for the genetic component of
ASD, where the interplay between commonly inherited
variants (single nucleotide polymorphism or SNPs) and
highly penetrant rare variations results with a complex
genetic architecture [15]. A small proportion of ASD cases
has been associated to de novo copy number variations
(CNV), including deletions and duplications, as well as to
de novo pathogenic single nucleotide variations (SNVs),
accounting for a total of 3% of cases according to recent
estimates [16]. Furthermore, ASD related syndromes for
which the genetic cause is known account for additional
3.4% of ASD. These data support a polygenic model,
where most ASD liability resides with many common vari-
ations along the genome, although the total genetic contri-
bution to ASD (including de novo variations, syndromic
mutations, non-additive and additive SNP effects) does
not exceed 60%, with the remaining proportion being un-
accounted for [16]. Still, the increased number of rare var-
iants exhibiting large individual effect sizes leaves open
the single major gene model, consistent with earlier esti-
mates suggesting about 10 to 20% of ASD cases to be due
to known genetic abnormalities [17].
The most common ASD associated syndromes in-
clude: i) Fragile X syndrome (caused by expansion of
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polymorphic CGG repeat upstream of the FMR1 gene)
in which over 40% show Autism core symptoms; ii)
Angelman syndrome, determined by a deletion of 15q11–
13 where ASD is present in about 50% of cases; iii) Tuber-
ous Sclerosis, due to mutations in two functionally-related
genes, TSC1 and TSC2, in which autism is present in more
than 60% cases; iv) 22q deletion (or Phelan-McDermid)
syndrome where about 80% of cases present with autistic
symptoms [16].
Recent sequencing approaches (including exome- or
whole-genome sequencing) have contributed to the
identification (or validation) of highly penetrant rare
genetic variants, including CHD8, GRIN2B, SCN2A, and
SYNGAP1 [18] (see also [19] for a recent review). De
novo mutations associated to ASD are often located in
genes functionally correlated. Among them, neuroligin 3
and 4 (NLGN3 and NLGN4), Neurexin3, SHANK3 and
CNTNAP2, which are all involved in synapse formation
and specialization, supporting the notion that altered syn-
aptic formation can lead to abnormal neural pathways in
ASD) [6]. However, it is important to underline that no
single neurobiological hypothesis yet can explain the aeti-
ology of ASD, which is still elusive and likely to be deter-
mined by multiple genetic and non-genetic factors.
As far as the contribution from commonly inherited
variants, the advent of affordable high-throughput geno-
typing technologies allowing for genome-wide associ-
ation studies (GWAS), combined with the increased
availability of ASD collections, is beginning to pay-off.
Although limited in statistical power to robustly identify
genome-wide significant loci, early studies have shown
the potential of GWAS in the identification of putative
novel risk variants [20]. Two of the first GWAS in ASD
reported the identification of common genetic variants
residing between two genes mapping on the chromo-
some 5 and coding for cell molecule adhesion proteins
(cadherin 9 and cadherin 10), providing support to a
previously hypothesized altered neuronal cell adhesion
in ASD [21, 22]. A third study, based on a broad collab-
orative effort, lead to the identification of an additional
common variant on chromosome 5, adjacent to several
genes including SEMA5A, a member of semaphorin pro-
tein involved in axonal guidance [23]. Later, the Autism
Genome Project (AGP, The AGP Consortium, representing
more than 50 centers in North America and Europe) iden-
tified genome-wide association signals for SNPs located in
the gene MACROD2 [24] and CNTNAP2, a gene previ-
ously implicated in ASD [25]. Most of the above findings
were not replicated in a subsequent meta-analysis in Euro-
pean samples [26, 27], suggesting the need for larger ASD
cohorts to clarify the role of common variation in the dis-
order. Large-scale coordinated international collaborations
such as the Psychiatry Genomic Consortium (PGC) have
been established, with the aim of conducting statistically
rigorous and comprehensive GWAS meta-analyses for
major psychiatric disorders [28, 29]. The first meta-analysis
of the ASD Working Group of the Psychiatric Genomics
Consortium, conducted on over 16,000 ASD individuals
has been recently published [30]. The study did not show
individual variants exceeding the accepted GWAS thresh-
old in the discovery dataset. However, it was able to identify
a novel and genome-wide significant association on
chromosome 10q24.32 (mapping in CUEDC2) in the com-
bined meta-analysis and confirmed among top-ranking as-
sociations some of the findings from previous GWAS.
Notwithstanding the impact of modern genome-wide
approaches in the dissection of the complex genetic
component of ASD, the vast majority of it is still to be
unveiled. The analysis of larger and, in particular, clinic-
ally well-characterized ASD samples is critical for the
identification of new genetic variants and their valid-
ation, and for establishing of genotype-phenotype corre-
lations. With these premises, the ‘Fondazione Smith
Kline’ has supported the creation of an area for autism
research that has launched the Italian Autism Network
(ITAN) initiative. This initiative aims to create a reposi-
tory of biological material (DNA, RNA and plasma) and
a database of clinical information on autism individuals
and their first-degree relatives enabling research on the
aetiology and phenomenology of ASD. The recruitment
of the first families began back in 2008. In this article,
we describe the protocol used by all recruiting sites for
clinical evaluation of the ASD subjects and relatives. We
also provide the main clinical features of the 249 re-
cruited families.
Methods
Study design
The ‘Fondazione Smith Kline’ Italy, with its “Autism Re-
search Area”, subsequently spun out as a separate Founda-
tion (“ITAN - Italian Autism Network”), has sponsored a
multi-centric project to recruit and assess autism individ-
uals and their first-degree relatives to create a repository
of genomic DNA, plasma, peripheral RNA and lympho-
blastoid cell lines (LCLs). Extensive clinical data and med-
ical history of autistic subjects and their first-degree
relatives have also been stored in the database. The goal of
the project is to build a biorepository that interacts with a
database of extensive clinical information collected elec-
tronically at each recruiting sites, enabling genetic, gen-
omic and proteomic research on ASD. Although the
target research areas are multidisciplinary (from genetic
and biomarker research, to epidemiological studies), the
design of the project was driven mainly by its genetic
goals. The project aims at collecting small families formed
by a proband (ASD child), a sibling when available, and
their parents. The collection of families would allow
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performing family-based genetic association studies as
well as the screening of genetic variants in cases and af-
fected and unaffected first-degree relatives.
Recruiting sites and ethical issues
The biorepository is hosted by the Department of Neu-
rosciences, Biomedicine and Movement Sciences at the
University of Verona, Italy. Recruitment has begun in
2008 and has been conducted thus far at thirteen differ-
ent Italian sites (Verona, Acireale (Catania), Bari, Bol-
ogna, Brescia, Cagliari, Lecco, Napoli, Padova, Pisa,
Rimini, Roma, and Troina (Enna).
Approximately half (48%) of the patients recruited
were referred by the primary care physician, 31% by a
tertiary care center, and the rest by schools, or out-
patient clinics.
A study protocol for the clinical assessment and sam-
ple management was written and agreed by the main
centers and founding members of the network. Candi-
date recruiting sites were selected among clinical centers
with a demonstrated ability to assess autism families as
described in the project protocol. The study and its
protocol were approved by the Azienda Ospedaliera
Universitaria Integrata of Verona Ethic Review Board.
Furthermore, each recruiting site obtained independent
approval to conduct the project by their respective local
ethical review committees. Eighteen sites joined the Ital-
ian Autism Network, with thirteen actively recruiting.
All adult subjects participating in this project gave their
written consent (or the consent for their chidren) to do-
nate biological samples and clinical and demographic in-
formation to participate in this study; assent to
participate to this study from the children was obtained
whenever possible.
Subjects
Cases, parents and, whenever available, sibling and/or
non-affected individuals identified as controls, were re-
cruited. Based on the selection criteria and the family
composition, different type of families can be summarized
through the pedigree analysis. We used the R package kin-
ship2 with the pedigree shrinking function to gain a
metric of pedigree structure in terms of bitSize (a measure
is defined as 2 * # NonFounders - # Founders, see [31]).
Inclusion and exclusion criteria
A proband child or affected sibling was eligible for re-
cruitment when all the following inclusion criteria apply:
1) at least 4 years of age at the time of the interview, 2)
having at least one parent or legal guardian giving volun-
tary written consent for their children to take part to the
research project, 3) meeting DSM-IV criteria for Autistic
Disorder or Asperger’s Disorder, or Pervasive Develop-
mental Disorder Not Otherwise Specified (PDD-NOS),
4) reaching score cut-off in ADI-R. Siblings of the pro-
band were recruited when available, and defined as un-
affected, if they met the following criteria: 1) at least
4 years of age at the time of recruitment, 2) devoid of
any comorbid psychiatric illness as determined by: i) the
Child Behavioural Checklist (CBCL) or by the Kiddie
Schedule for Affective Disorders and Schizophrenia for
children (Kiddie-SADS), ii) absence of social skills im-
pairment as determined by the Social Responsiveness
Scale (SRS), iii) the Broader Phenotype Autism Symptom
Scale (BPASS) (administered to evaluate the presence of
autism spectrum symptoms). Individuals were not eli-
gible for recruitment if any of the following criteria
apply: 1) history of serious head injury, encephalitis or
tumors, 2) age above 18; 3) Diagnoses of Childhood Dis-
integrative Disorder or Rett Syndrome, diagnosis of
known ASD-related genetic syndromes or presence of
severe mental retardation (IQ < 20) that would com-
promise the validity of the diagnosis of autism.
Clinical assessment
Diagnosis was established by experienced child psychia-
trists after completing full neurological, psychiatric and
physical examination, and after reviewing and completing
the Autism Diagnostic Interview – Revised (ADI-R) and
the Autism Diagnostic Observation Schedule (ADOS) that
were administered by trained and certified clinicians. The
cognitive level of children was assessed whenever possible
through either one of the following scales: Wechsler
Intelligence Scale for Children, Wechsler Preschool and
Primary Scale of Intelligence, Leiter International Per-
formance Scale or Griffiths Mental Developmental Scale.
Additional structured evaluation included the Children’s
Global Assessment Scale (CGAS) and, for subjects with
suspect of Asperger’s Disorder, the Krug Asperger’s Dis-
order Index (KADI). The KADI is an individually adminis-
tered, norm-referenced screening instrument that
provides useful information for determining the diagnosis
of Asperger’s Disorder. It is standardized for use with indi-
viduals 6 through 21 years of age. Instrumental and la-
boratory examination of the fragile X (FRAX) expansions
and major cytogenetic abnormalities were conducted for
all the autism individuals and their siblings. MRI scan and
awake and nap EEG were evaluated in all patients, if they
were not available from previous assessments conducted
at a close time.
Parents of the probands and siblings of age 18 and
above were assessed as follows: i) Cognitive level: four
items of the WAIS (arithmetic, vocabulary, block design,
picture arrangement); ii) Language: Token test; iii) Aut-
ism spectrum symptoms: BPASS Broader Phenotype
Autism Symptom Scale (BPASS); iv) Psychopathology:
SCID screening interview.
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Non-affected siblings of less and 18 years of age re-
cruited were assessed with medical, psychiatric and
neurologic examination. For each non-affected sibling,
cognitive levels are established via the four items of the
Wechsler Intelligence Scale for Children (WISC) that
has shown to produce a reliable measure of IQ [32]. The
four items include the arithmetic, vocabulary, block de-
sign, and picture arrangement. Language competence was
assessed with the Peabody Picture Vocabulary test
(PPVT-R), for ages between 4 and 12, and the Token Test
for age between 12 and 18. Social Responsiveness Scale
(SRS) was also administered to evaluate socialization. Psy-
chopathology in non-affected siblings was assessed via the
Child Behavioural Checklist (CBCL). The following defini-
tions were used to define the presence of psychopath-
ology: T-score: normal < 65; at risk: 66–74; pathological:
> 75 (2.5 SD from normal average) if scores less above 75
(presence of psychopathology) the Kiddie-SADS interview
is administered to diagnose the psychiatric interview.
Sample collection, handling and storage
The Italian Autism Network collected DNA, plasma,
RNA and EBV transformed lymphocytes in the biorepo-
sitory from each of the individuals assessed. From all in-
dividuals eligible to participate in this project (as either
cases or unaffected relatives) for whom a signed in-
formed consent was obtained, the following peripheral
blood samples were taken: 1) 2 × 6-mL in ACD blood
tubes for DNA extraction; 2) 1 × 6 mL ACD tube for
extracting lymphocytes to be transformed with Epstein
Barr virus (EBV) in LCLs; 3) 1 × 6-mL in EDTA tube to
obtain plasma aliquots for proteomic analysis, and 4)
2 × 2.5-mL in PAX gene tubes for obtaining RNA.
Plasma aliquots (0.2 mL) were prepared by centrifugation
of EDTA tubes and stored at -80 °C. Blood-derived sam-
ples for RNA extraction were prepared by gently mixing
PAX gene tubes, storing them for 2 h at room
temperature, cooling them at –20o and later at -80 °C to
be ready for shipment. Samples for DNA extraction and
cell lines transformation were shipped at room
temperature to the biorepository on the same day of col-
lection. Frozen samples (plasma, blood samples for RNA)
were shipped via express courier in dry ice to the
biorepository.
Upon delivery at the biorepository, Plasma aliquots
and PAX gene tubes were stored at -80 °C. DNA extrac-
tion was performed using the Puregene Blood Kit (Gen-
tra Systems, Minneapolis, MN, US), a modified
salting-out precipitation method, following the manufac-
turer’s instructions. Each DNA sample was then quality
controlled and quantified using NanoDrop ND 1000
spectrophotometer (Thermo Scientific, Wilmington, DE,
US). RNA samples from lymphocytes were isolated with
QIAcube system, quantified with NanoDrop and ana-
lyzed for quality control by use of the RNA 6000 Nano-
LabChip (Agilent Technologies, Santa Clara, CA, US).
The biorepository also transformed the lymphocytes
with EBV into lines that were and then stored in Liquid
Table 1 Distribution of subjects among recruiting centers and summary of demographic information
Site Families Parents Unaffected
siblings
Autism Spectrum Disorders
ASD
cases
Gender
(%
males)
Average
Age (SD)
Ethnicity Diagnosis
AFR OTH CEU AD ASPG PDD-NOS
3 66b 122 57 68 85.29 9.44 (3.84) 8 0 60 50 9 9
4 4b 8 0 5 100.00 10.60 (1.67) 0 0 5 3 0 2
5 27a 51 1 26 92.31 5.38 (2.17) 0 2 24 18 0 8
6 21b 41 7 22 72.73 9.45 (4.68) 11 0 11 18 1 3
7 17 33 10 17 82.35 10.71 (4.55) 8 3 6 13 3 1
8 32a 51 0 31 83.87 6.71 (2.77) 16 0 15 5 2 24
9 17 31 11 17 88.24 11.24 (4.12) 0 0 17 11 1 5
10 8b 16 1 9 88.89 7.89 (3.95) 2 0 7 6 0 3
11 13 23 2 13 76.92 11.77 (4.55) 4 0 9 4 6 3
12 11b 22 3 12 75.00 5.25 (1.71) 0 0 12 4 0 8
13 9a 15 2 8 87.50 10.88 (2.85) 0 1 7 5 1 2
16 4 8 3 4 100.00 10.50 (5.51) 0 0 4 4 0 0
17 20 40 2 20 95.00 10.05 (4.67) 2 0 18 12 2 6
Tot 249 461 99 252 86.78 9.22 (3.62) 51 6 195 153 25 74
Distribution of subjects among recruiting centers and summary of demographic information
aindicates centers where family recruitment is not completed (eg affected subjects less than N of families)
bIndicates centers which have recruited families with > 1 affected subjects
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Nitrogen. All relevant data regarding the samples are en-
tered into a computerized system that allows matching
the information of the samples with the clinical data
stored in the centralized clinical database.
Data security procedure for the clinical database
All blood, plasma, cell lines, DNA and RNA samples are
coded and stored under secure conditions with re-
stricted access according to the Italian privacy policies
required for keeping secure sensitive data. The clinical
information collected at each site is entered into an
encrypted system and stored in a database. Codes corre-
sponding to the research subjects are known only by the
clinician responsible for the research project, who ob-
tained the informed consent from the parents of affected
subjects and any sibling at each recruiting site (Site Prin-
cipal Investigator), and by the clinical personnel directly
involved in the assessment of the research subject, as re-
quired by standard clinical practice.
Discussion
The Italian Autism Network (ITAN) was initiated under
the sponsorship of the Fondazione Smith Kline with the
aim of creating an open resource for clinical, genetics
and biomarker research in autism. Here we describe the
protocol used to build up this novel family collection
and the associated database and biorepository. Each
family is composed by at least one ASD affected child
and, when possible, a discordant sibling.
Recruitment progress to date
To date, the ITAN consortium has recruited 812 sub-
jects, i.e. 252 probands and 560 first degree relatives, for
a total of 249 families. In Table 1 we provide information
on the distribution of samples among recruiting centers
and the demographic of the collection. In Fig. 1 we
Fig. 1 Pedigree structures of families recruited into the ITAN collection based on the bitSize measure (only most represented pedigree structures
are shown, for a total of 245 families out of 249). For each pedigree structure, the number of families of the ITAN dataset are reported
Fig. 2 distribution of the cognitive level of ASD subjects of the ITAN
collection, as measured by IQ assessments, for each of the three
diagnostic categories
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illustrate the distribution of pedigree structures among
families recruited in the study.
Clinical phenotypes
The clinical assessment was derived by full neuropsychi-
atric evaluation and structured interviews (i.e.: ADI-R,
and ADOS) by appropriately trained and certified staff.
The average age at interview of the affected and
non-affected subjects recruited to date is 8.89 and 11.53,
respectively, while the ratio of males in the affected sam-
ples is 85.31%, reflecting the higher incidence of autism
in males reported for the disease in the general popula-
tion. For the non-affected siblings, the proportion of
males is 55.55%. Figure 2 reports the distribution of the
cognitive level for each diagnostic category (DSM IV), as
measured by IQ assessment. As expected, high function-
ing Asperger subjects have higher values of IQ com-
pared to PDD-NOS and AD subject group (the latter
showing the lowest IQ values). Only 7.1% of the affected
subjects (n = 18) have serious mental retardation with a
low IQ (< 35) as shown in Table 2. It should be however
noted, that IQ below 20 was an exclusion criterion for
the probands.
Preliminary genetic investigations
So far, DNA samples from subjects of the ITAN collection
have been utilized for testing candidate risk variants for aut-
ism derived from large GWAS investigations [26, 27, 33].
Furthermore, the regulation of candidate genes has been
studied by analyzing RNA expression in LCLs from selected
probands and non-affected siblings [34]. A large proportion
of the discordant sibling pairs (for a total of 152 samples)
was genotyped on the PsychArray (Illumina Inc., San Diego,
California, USA) and blood RNA was sequenced on the
Illumina HiSeq 2000 RNA Seq Platform. The availability of
both genotype and RNA expression data on a genome scale
is being exploited for a novel integrative approach aimed at
the identification of genetical-genomic biomarker signa-
tures for autism [35, 36].
In conclusion, the ITAN collection clearly represents a
valuable resource for the identification and characterization
of common and rare genetic risk variants for autism, thanks
to the accuracy of the clinical assessment and the family de-
sign. The availability of different types of biological samples
makes it a unique collection for the conduct of biomarkers
investigations integrating multiple “omic” platforms.
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